Acute Treatment for Improvement of Cognition

PH15 is an investigational pherine nasal spray with a novel, rapid-onset potential mechanism of action (MOA) that is fundamentally differentiated from the MOA of all currently approved treatments to improve cognitive impairment caused by mental fatigue and potentially other disorders. Vistagen believes PH15 has the potential to improve cognitive and psychomotor performance and improvement of reaction time in individuals with mental fatigue.

Vistagen is currently evaluating the path forward for PH15, including assessing studies Vistagen believes will be necessary to submit a U.S. IND for further Phase 2 clinical development of PH15, on its own or with collaborators, as well as evaluating the appropriate indication for demonstrating improvement of cognitive function.

For more information on partnering with Vistagen, please contact us at bd@vistagen.com.